Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy

Publication date: July 2017
Source:Surgical Oncology Clinics of North America, Volume 26, Issue 3
Author(s): Tu Dan, Noelle L. Williams

Teaser

Early stage non–small cell lung cancer is a growing clinical entity with evolving standards of care. With the adoption of lung screening guidelines, the incidence of early stage disease is expected to increase. Surgical resection for early stage disease has been considered standard of care; however, there is evidence that stereotactic ablative radiation therapy (SABR) may be a viable alternate to surgery. In the last decade, advances in image guidance, treatment planning systems, and improved spatial accuracy of treatment delivery have converged to result in the effective use of SABR in the treatment of early stage lung cancer.


http://ift.tt/2rDq2Q5